UPDATE: Morgan Stanley Reiterates Equal-Weight Rating on Catamaran Corp Following Salveo Acquisition

In a report published Thursday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Equal-Weight rating on

and maintained the $45.00 price target. In the report, Morgan Stanley noted, “The acquisition of Salveo Specialty Pharmacy marks CTRX's M&A debut since Restat in 8/2013. While estimated EBITDA contribution of ~$20 million is below expectations, the acquisition is aligned with management's strategy of building a specialty franchise and could help build CTRX offering in the fastest growth area in the market.” Catamaran Corp. closed on Wednesday at $42.56.